Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Frequent ESR1 and CDK Pathway Copy Number Alterations in Metastatic Breast Cancer.

Basudan A, Priedigkeit N, Hartmaier RJ, Sokol ES, Bahreini A, Watters RJ, Boisen MM, Bhargava R, Weiss KR, Karsten MM, Denkert C, Blohmer JU, Leone JP, Hamilton RL, Brufsky AM, Elishaev E, Lucas PC, Lee AV, Oesterreich S.

Mol Cancer Res. 2018 Oct 24. pii: molcanres.0946.2018. doi: 10.1158/1541-7786.MCR-18-0946. [Epub ahead of print]

PMID:
30355675
2.

The Evolution of Estrogen Receptor Signaling in the Progression of Endometriosis to Endometriosis-Associated Ovarian Cancer.

Andersen CL, Boisen MM, Sikora MJ, Ma T, Tseng G, Suryawanshi S, Vlad A, Elishaev E, Edwards RP, Oesterreich S.

Horm Cancer. 2018 Dec;9(6):399-407. doi: 10.1007/s12672-018-0350-9. Epub 2018 Oct 9.

PMID:
30302736
3.

Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival.

Ross MS, Burriss ME, Winger DG, Edwards RP, Courtney-Brooks M, Boisen MM.

Gynecol Oncol. 2018 Aug;150(2):306-310. doi: 10.1016/j.ygyno.2018.06.008. Epub 2018 Jun 19.

PMID:
29929924
4.

Outcomes of stage II endometrial cancer: The UPMC Hillman Cancer Center experience.

Chen KS, Berhane H, Gill BS, Olawaiye A, Sukumvanich P, Kelley JL, Boisen MM, Courtney-Brooks M, Comerci JT, Edwards R, Berger J, Beriwal S.

Gynecol Oncol. 2017 Nov;147(2):315-319. doi: 10.1016/j.ygyno.2017.08.021. Epub 2017 Aug 31.

PMID:
28866431
5.

Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens.

Andersen CL, Sikora MJ, Boisen MM, Ma T, Christie A, Tseng G, Park Y, Luthra S, Chandran U, Haluska P, Mantia-Smaldone GM, Odunsi K, McLean K, Lee AV, Elishaev E, Edwards RP, Oesterreich S.

Clin Cancer Res. 2017 Jul 15;23(14):3802-3812. doi: 10.1158/1078-0432.CCR-16-1501. Epub 2017 Jan 10.

6.

Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.

Boisen MM, Lesnock JL, Richard SD, Beriwal S, Kelley JL, Zorn KK, Edwards RP.

Int J Gynecol Cancer. 2016 May;26(4):626-31. doi: 10.1097/IGC.0000000000000667.

PMID:
27051048
7.

High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome.

Delgado E, Boisen MM, Laskey R, Chen R, Song C, Sallit J, Yochum ZA, Andersen CL, Sikora MJ, Wagner J, Safe S, Elishaev E, Lee A, Edwards RP, Haluska P, Tseng G, Schurdak M, Oesterreich S.

Gynecol Oncol. 2016 May;141(2):348-356. doi: 10.1016/j.ygyno.2016.02.030. Epub 2016 Mar 11.

8.

Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancers: is there a role?

Boisen MM, Richard SD, Holtzman MP, Edwards RP, Kelley JL, Choudry MH, Bartlett D, Huang M.

J Gastrointest Oncol. 2016 Feb;7(1):10-7. doi: 10.3978/j.issn.2078-6891.2015.103.

9.

Surgical Outcomes of Patients Undergoing Extrafascial Hysterectomy After Neoadjuvant Radiotherapy With or Without Chemotherapy for Locally Advanced Endometrial Cancer Clinically Extending to the Cervix or Parametria.

Boisen MM, Vargo JA, Beriwal S, Sukumvanich P, Olawaiye AB, Kelley JL, Edwards RP, Huang M, Courtney-Brooks M, Comerci JT.

Int J Gynecol Cancer. 2017 Jul;27(6):1149-1154. doi: 10.1097/IGC.0000000000000614.

PMID:
26825835
10.

Nausea as a sentinel symptom for cytotoxic chemotherapy effects on the gut-brain axis among women receiving treatment for recurrent ovarian cancer: an exploratory analysis.

Donovan HS, Hagan TL, Campbell GB, Boisen MM, Rosenblum LM, Edwards RP, Bovbjerg DH, Horn CC.

Support Care Cancer. 2016 Jun;24(6):2635-42. doi: 10.1007/s00520-015-3071-4. Epub 2016 Jan 8.

11.

Treating gynecologic malignancies with selective estrogen receptor downregulators (SERDs): promise and challenges.

Boisen MM, Andersen CL, Sreekumar S, Stern AM, Oesterreich S.

Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:322-33. doi: 10.1016/j.mce.2015.04.035. Epub 2015 Aug 11.

PMID:
26276546
12.

Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria.

Vargo JA, Boisen MM, Comerci JT, Kim H, Houser CJ, Sukumvanich P, Olawaiye AB, Kelley JL, Edwards RP, Huang M, Courtney-Brooks M, Beriwal S.

Gynecol Oncol. 2014 Nov;135(2):190-5. doi: 10.1016/j.ygyno.2014.09.001. Epub 2014 Sep 9.

PMID:
25218303

Supplemental Content

Loading ...
Support Center